Medtronic to acquire Biophan MRI Safety Technology for m | MRI
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
MRI Medtronic to acquire Biophan MRI Safety Technology for $11m

Medtronic to acquire Biophan MRI Safety Technology for $11m

Radiology News
Biomedical technology developer Biophan Technologies, Inc., announced that the company has entered into a definitive agreement with Medtronic, Inc., to acquire Biophan's MRI safety patents in a transaction worth $11m in cash. Biomedical technology developer Biophan Technologies, Inc., announced that the company has entered into a definitive agreement with Medtronic, Inc., to acquire Biophan's MRI safety patents in a transaction worth $11m in cash. The transaction is anticipated to close within 60 days.

Under the terms of the agreement, Biophan will transfer to Medtronic its MRI safety patent portfolio, which includes technologies that make medical devices, such as pacemakers, safe for use with MRI.

"Since our founding in 2000, our goal has been to develop and commercialize innovative technologies related to medical imaging safety, with a focus on the development of solutions for the contraindication between pacemakers and MRI machines," stated Mr. Guenter Jaensch, Chairman of Biophan's Board of Directors.

"Our technology has the potential to solve the problems that have prevented many people with pacemakers from having an MRI. We believe Medtronic has the experience and resources to bring our technology to market," stated Michael Weiner, President of Biophan.

Biophan will continue its efforts to develop technologies to enable visualization of clotting and restenosis in stents under MRI, which is not possible with today's stents. In addition, it will continue its collaboration with Myotech on the development of the Myotech Circulatory Support System, a novel device for the treatment of acute heart failure.
 

Related Articles

Breaking News